Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations

Tamburin S., Park S. B., Schenone A., Mantovani E., Hamedani M., Alberti P., ...More

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.171, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 171
  • Publication Date: 2022
  • Doi Number: 10.1016/j.critrevonc.2021.103575
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Keywords: Evidence-based medicine, Exercise, Physical therapy, Rehabilitation, Treatment, Chemotherapy-induced peripheral neurotoxicity (CIPN), QUALITY-OF-LIFE, RANDOMIZED CONTROLLED-TRIAL, CANCER-PATIENTS, NEUROPATHY, THERAPY, PREVENTION, SYMPTOMS, PATHOGENESIS, ASSOCIATION, MULTICENTER
  • Hacettepe University Affiliated: Yes


Pharmacological strategies for chemotherapy-induced peripheral neurotoxicity (CIPN) are very limited.We systematically reviewed data on rehabilitation, exercise, physical therapy, and other physical non-pharmacological interventions and offered evidence-based recommendations for the prevention and treatment of CIPN.A literature search using PubMed, Web of Science and CINAHL was conducted from database inception until May 31st, 2021.2791 records were title-abstract screened, 71 papers were full-text screened, 41 studies were included, 21 on prevention and 20 on treatment of CIPN. Treatment type, cancer type, chemotherapy compounds were heterogeneous, sample size was small (median: N = 34) and intention-to-treat analysis was lacking in 26/41 reports.Because of the methodological issues of included studies, the reviewed evidence should be considered as preliminary. Exercise, endurance, strength, balance, and sensorimotor training have been studied in low-to-moderate quality studies, while the evidence for other treatments is preliminary/inconclusive. We offer recommendation for the design of future trials on CIPN.